Premium
Pharmacologic effects and physiologic disposition of delta 6a,10a dimethyl heptyl tetrahydrocannabinol (DMHP) in man
Author(s) -
Lemberger Louis,
McMahon Robert,
Archer Robert,
Matsumoto Ken,
Rowe Howard
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974154380
Subject(s) - delta 9 tetrahydrocannabinol , medicine , euphoriant , anesthesia , urine , supine position , endocrinology , cannabinoid , receptor , psychiatry
14 C‐DMHP (200 µg/70 kg man) was administered by the intravenous route to 3 healthy male casual marihuana smokers. Tachycardia occurred within 10 minutes and persisted for from 11 1/2 to 6 hours. Blood pressure fell slightly with time when subiects were supine, while standing for less than 1 minute resulted in marked hypotension. In these 3 subjects, except for dizziness on standing there were essentially no demonstrable psychologic effects, neither euphoria nor dysphoria. Subiects did, however, report symptoms similar to those after marihuana or Δ 9 ‐THC, including dry mouth, decreased salivation, and drowsiness. After intravenous dimethyl heptyl tetrahydrocannabinol (DMHP), plasma levels of total radioactivity and 14 C‐DMHP declined in a multiphasic fashion; the half‐life of the terminal phase for DMHP was 39 hours. Approximately 69% of the administered radioactive dose was recovered in 7 days. Radioactivity was excreted predominantly in the feces (58%) and to a lesser extent in urine (11%) during the 7 day collection period.